Search

Your search keyword '"Herceptin (Medication) -- Reports"' showing total 137 results
Start Over Descriptor "Herceptin (Medication) -- Reports"
137 results on '"Herceptin (Medication) -- Reports"'

1. Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight

Subjects
Business -- Research, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

M2 PRESSWIRE-May 5, 2023-: Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight (C)1994-2023 M2 COMMUNICATIONS RDATE:04052023 DelveInsight's, 'Trastuzumab Biosimilar Insight, 2023' report provides comprehensive insights about 35+ companies and 35+ marketed [...]

Published
2023

2. Study Findings from Sookmyung Women's University Provide New Insights into siRNA-Based Therapy (Let-7 Mirna and Cdk4 Sirna Co-encapsulated In Herceptin-conjugated Liposome for Breast Cancer Stem Cells)

Subjects
Cancer treatment -- Reports, Women's health -- Reports, Stem cells -- Reports, Breast cancer -- Reports, Stem cell research -- Reports, Stem cell transplantation -- Reports, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2020 OCT 8 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Biotechnology - siRNA-Based Therapy is the subject of a report. According [...]

Published
2020

3. Researchers at Shanghai Henlius Biotech Discuss Findings in Biotherapies and Biologicals (Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin? with a Panel of Sensitive and Orthogonal Methods Including a Novel ...)

Subjects
Biotechnology -- Reports -- Methods, Women's health -- Methods -- Reports, Therapeutics -- Reports -- Methods, Trastuzumab -- Reports -- Methods, Antineoplastic agents, Editors, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2020 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Drugs and Therapies - Biotherapies and Biologicals. According to [...]

Published
2020

4. Tarbiat Modares University Researchers Report Research in Cancer Gene Therapy (Phospholipase-Cg1 Signaling Protein Down-Regulation By Oligoclonal-VHHs Based Immuno-Liposome: A Potent Metastasis Deterrent In HER2 Positive Breast Cancer Cells)

Subjects
Cancer treatment -- Reports, Cancer genetics -- Genetic aspects -- Research -- Reports, Genetic research -- Reports, Gene therapy -- Reports, Women's health -- Reports, Cancer research -- Reports, Genes -- Reports, Phospholipases -- Reports, Biochemistry -- Reports, Antibodies -- Reports, Breast cancer -- Genetic aspects -- Research -- Reports, Cancer metastasis -- Genetic aspects -- Research -- Reports, Anopheles, Cancer cells, Editors, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2020 APR 9 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on cancer gene therapy have been published. According to news reporting [...]

Published
2020

5. Researchers from Baqiyatallah University of Medical Sciences Report on Findings in Breast Cancer (Breast Cancer Targeted/ Therapeutic with Double and Triple Fusion Immunotoxins)

Subjects
Cancer treatment -- Reports, Women's health -- Reports, Cancer research -- Reports, Immunotoxins -- Reports, Breast cancer -- Research -- Reports, Tumors, Editors, Cancer patients, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2020 MAR 26 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Oncology - Breast Cancer are discussed in a new report. According [...]

Published
2020

6. New Breast Cancer Findings Reported from University of Manchester (Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer)

Subjects
Women's health -- Models -- Reports, Breast cancer -- Research -- Models -- Reports, Antineoplastic agents -- Research -- Models -- Reports, Epidermal growth factors, Genes, Tyrosine, Cancer research, Anopheles, Phenols (Class of compounds), Editors, Women, Health, Women's issues/gender studies, University of Manchester -- Reports, Herceptin (Medication) -- Reports
Abstract

2019 AUG 15 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on Oncology - Breast Cancer is now available. According to news [...]

Published
2019

7. Findings on Breast Cancer Described by Researchers at University of Gdansk (Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells)

Subjects
Women's health -- Reports, Cancer research -- Reports, Biochemistry -- Reports, Breast cancer -- Development and progression -- Research -- Reports, Cancer cells, Laminin, Editors, Women, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2019 JUN 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Oncology - Breast Cancer is the subject of a report. According [...]

Published
2019

8. Herceptin (Trastuzumab) Biosimilars Market 2021: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars - ResearchAndMarkets.com

Subjects
Pertuzumab -- Reports, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

DUBLIN -- The 'Herceptin (Trastuzumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships' report has been added to ResearchAndMarkets.com's offering. The HER2 [...]

Published
2021

9. Global Herceptin (Trastuzumab) Biosimilars Pipeline Guide 2021

Subjects
Pertuzumab -- Reports, Banking, finance and accounting industries, Business, Herceptin (Medication) -- Reports
Abstract

Dublin, Oct 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- The 'Herceptin (Trastuzumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships' report has [...]

Published
2021

10. Herceptin (Trastuzumab) Biosimilars Market 2021: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars

Subjects
Pertuzumab -- Reports, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

M2 PRESSWIRE-October 20, 2021-: Herceptin (Trastuzumab) Biosimilars Market 2021: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars (C)1994-2021 M2 COMMUNICATIONS RDATE:20102021 The 'Herceptin (Trastuzumab) Biosimilars: [...]

Published
2021

11. HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030

Subjects
Strategic planning (Business) -- Forecasts and trends -- Reports, Biological products -- Reports -- Forecasts and trends, Breast cancer -- Reports -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary, Kadcyla (Medication) -- Reports, Perjeta (Medication) -- Reports, Herceptin (Medication) -- Reports
Abstract

New York: ReportLinker has issued the following news release: Reportlinker.com announces the release of the report 'HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030' - https://www.reportlinker.com/p06151171/?utm_source=GNW [...]

Published
2021

12. HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030

Subjects
Strategic planning (Business) -- Forecasts and trends -- Reports, Biological products -- Reports -- Forecasts and trends, Breast cancer -- Reports -- Forecasts and trends, Market trend/market analysis, Business, international, Law, Kadcyla (Medication) -- Reports, Perjeta (Medication) -- Reports, Herceptin (Medication) -- Reports
Abstract

(GlobeNewswire) - Reportlinker.com announces the release of the report 'HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030' - https://www.reportlinker.com/p06151171/?utm_source=GNW The realization that introducing HER2-targeted therapies earlier [...]

Published
2021

13. HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030

Subjects
Strategic planning (Business) -- Reports -- Forecasts and trends, Biological products -- Reports -- Forecasts and trends, Breast cancer -- Reports -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business, Kadcyla (Medication) -- Reports, Perjeta (Medication) -- Reports, Herceptin (Medication) -- Reports
Abstract

New York, Sep 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Reportlinker.com announces the release of the report 'HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030' - [...]

Published
2021

14. Reports from University of Cincinnati Provide New Insights into Drug Delivery Systems [Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin [R]-conjugated PLGA-PEG nanoparticles for drug delivery]

Subjects
University of Cincinnati -- Reports, Herceptin (Medication) -- Reports, Reports, Drug delivery systems -- Reports, Physical fitness -- Reports
Abstract

2018 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Drugs and Therapies - Drug Delivery Systems are discussed [...]

Published
2018

15. Investigation Report on China's Trastuzumab Market 2021-2025 Featuring Roche Pharma (Schweiz) AG (HERCEPTIN) & Shanghai Henlius Biotech (ZERCEPAC)

Subjects
Biotechnology -- Reports -- Forecasts and trends -- Investigations, Stomach cancer -- Investigations -- Forecasts and trends -- Reports, Company legal issue, Market trend/market analysis, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

M2 PRESSWIRE-May 6, 2021-: Investigation Report on China's Trastuzumab Market 2021-2025 Featuring Roche Pharma (Schweiz) AG (HERCEPTIN) & Shanghai Henlius Biotech (ZERCEPAC) (C)1994-2021 M2 COMMUNICATIONS RDATE:06052021 The 'Investigation Report on [...]

Published
2021

16. Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight

Subjects
Business -- Research, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

M2 PRESSWIRE-February 22, 2021-: Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight (C)1994-2021 M2 COMMUNICATIONS RDATE:20022021 DelveInsight's, 'Trastuzumab- Biosimilar Insight, 2020,' report provides comprehensive insights about 35+ companies and 35+ marketed [...]

Published
2021

17. Trastuzumab Biosimilars Landscape Report 2020 Featuring 36 Key Players & 32 Key Products - ResearchAndMarkets.com

Subjects
United States. Food and Drug Administration -- Reports, Stomach cancer -- Reports, Trastuzumab -- Reports, Business, Business, international, Kanjinti (Medication) -- Reports, Herceptin (Medication) -- Reports
Abstract

DUBLIN -- The 'Trastuzumab - Biosimilars Insight, 2020' report has been added to ResearchAndMarkets.com's offering. This Trastuzumab- Biosimilar Insight, 2020 report provides comprehensive insights about 35+ companies and 35+ marketed [...]

Published
2020

18. Trastuzumab Biosimilars Landscape Report 2020 Featuring 36 Key Players & 32 Key Products

Subjects
United States. Food and Drug Administration -- Reports, Trastuzumab -- Reports, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

M2 PRESSWIRE-September 8, 2020-: Trastuzumab Biosimilars Landscape Report 2020 Featuring 36 Key Players & 32 Key Products (C)1994-2020 M2 COMMUNICATIONS RDATE:08092020 The 'Trastuzumab - Biosimilars Insight, 2020' report has been [...]

Published
2020

19. New Breast Cancer Data Have Been Reported by Researchers at Tianjin Medical University Cancer Institute and Hospital (Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth ...)

Subjects
Killer cells -- Growth -- Reports, Women's health -- Reports, Cancer cells -- Reports, Cancer research -- Reports, Breast cancer -- Reports, Antineoplastic agents -- Reports, Company growth, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2017 DEC 7 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Oncology - Breast Cancer. According to news reporting out [...]

Published
2017

20. Studies from Attana AB Reveal New Findings on Breast Cancer (Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors)

Subjects
Herceptin (Medication) -- Reports, Research, Reports, Protein binding -- Reports, Physical fitness -- Reports, Anthracyclines -- Research -- Reports, Cancer cells -- Reports, Cancer research -- Reports, Chemotherapy -- Reports, Breast cancer -- Research -- Reports
Abstract

2017 MAR 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Oncology - Breast Cancer. According to news [...]

Published
2017

21. Research and Markets Releases Report: Herceptin (Trastuzumab) Biosimilars

Subjects
Pertuzumab -- Reports, Business, Business, international, Telecommunications industry, Herceptin (Medication) -- Reports
Abstract

Research and Markets has announced the addition of the 'Herceptin (Trastuzumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships' report to its [...]

Published
2021

22. Investigators at Pusan National University Report Findings in Breast Cancer (Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells)

Subjects
Women's health -- Reports, Cancer cells -- Reports, Breast cancer -- Research -- Reports, Antineoplastic agents -- Research -- Reports, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2016 DEC 1 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Oncology - Breast Cancer is the subject of a report. According [...]

Published
2016

23. Good News on Early Breast Cancer: Herceptin Treatment Can Be Shortened

Author

Grady, Denise

Subjects
Oncology, Experimental -- Reports, Antineoplastic agents -- Reports, Cancer -- Care and treatment -- Research, Breast cancer -- Drug therapy -- Reports, Antimitotic agents -- Reports, General interest, Herceptin (Medication) -- Reports
Abstract

Byline: DENISE GRADY Over the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more. The medicine, used [...]

Published
2018

24. CMI Adds Report on the Global Herceptin Biosimilar Market

Subjects
Roche Holding AG -- Forecasts and trends, Pertuzumab -- Forecasts and trends -- Reports, Hyaluronidase -- Reports -- Forecasts and trends, Biotechnology industries -- Forecasts and trends, Drug approval -- Forecasts and trends -- Reports, Trastuzumab -- Reports -- Forecasts and trends, Market trend/market analysis, Business, Business, international, Telecommunications industry, Herceptin (Medication) -- Reports
Abstract

According to Coherent Market Insights, the global herceptin biosimilar market is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 [...]

Published
2020

25. Recent Findings from Shanghai Henlius Biotech Advance Knowledge in Biotherapies and Biologicals (Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin? with a Panel of Sensitive and Orthogonal Methods Including a ...)

Subjects
Herceptin (Medication) -- Reports, Research, Reports, Methods, Biotechnology -- Reports -- Methods, Therapeutics -- Reports -- Methods, Trastuzumab -- Research -- Reports -- Methods, Antineoplastic agents, Editors
Abstract

2020 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- A new study on Drugs and Therapies - Biotherapies and Biologicals is now available. According [...]

Published
2020

26. New Findings from Xijing Hospital in the Area of Breast Cancer Reported (Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer)

Subjects
Women's health -- Analysis -- Reports, Breast cancer -- Research -- Analysis -- Reports, Cancer metastasis -- Research -- Analysis -- Reports, Antineoplastic agents -- Research -- Analysis -- Reports, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

2015 JUL 16 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Oncology are discussed in a new report. According to news reporting [...]

Published
2015

27. Ohio Medicaid overpaid $90,000 for cancer drug

Subjects
Medicaid -- Reports, Antineoplastic agents -- Reports, Business, General interest, Business, regional, Herceptin (Medication) -- Reports
Abstract

Byline: Katie Wedell April 07--A Medicaid billing error led to Ohio overpaying more than $90,000 for a cancer drug, according to a new report from the Health and Human Services [...]

Published
2017

28. European Medicine Agency new product:Herceptin

Subjects
Antineoplastic agents -- Reports, Business, international, Herceptin (Medication) -- Reports
Abstract

London: European Medicine Agency has issued the following new product details: This is a summary of the European public assessment report (EPAR) for Herceptin. It explains how the Committee for [...]

Published
2018

29. European Medicine Agency new product details:Herceptin

Subjects
Antineoplastic agents -- Reports, Business, international, Herceptin (Medication) -- Reports
Abstract

London: European Medicine Agency has issued the following new product details: This is a summary of the European public assessment report (EPAR) for Herceptin. It explains how the Committee for [...]

Published
2018

30. Researchers from Zhejiang University Report New Studies and Findings in the Area of Gastric Cancer (Target-specific Delivery of Oxaliplatin To Her2-positive Gastric Cancer Cells In Vivo Using Oxaliplatin-au-fe3o4-herceptin Nanoparticles)

Subjects
Herceptin (Medication) -- Reports, Reports, Research, Cancer -- Reports, Trastuzumab -- Research -- Reports, Oxaliplatin -- Research -- Reports, Drug delivery systems -- Reports, Cancer research -- Reports, Magnetite -- Reports, Stomach cancer -- Research -- Reports, Chemotherapy -- Reports, Iron oxides, Nanoparticles, Novels, Editors, Cancer cells, Retirement benefits, Technology
Abstract

2019 APR 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Oncology - Gastric Cancer are presented in a new report. According to [...]

Published
2019

31. Decision Resources Brings Out Report on Gastric Cancer in China

Subjects
Stomach cancer -- Care and treatment -- Reports, Arts and entertainment industries, Herceptin (Medication) -- Reports
Abstract

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issue, found that oncologists in China are embracing Roche's Herceptin as the targeted therapy for treating HER2+ gastric cancer. [...]

Published
2013

32. Research and Markets Adds Report: Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

Subjects
Genentech Inc. -- Reports, Biotechnology industry -- Reports, Stomach cancer -- Reports, Food and beverage industries, Herceptin (Medication) -- Reports
Abstract

Research and Markets has announced the addition of the 'Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors' report to its offerings. In a release, Research and Markets noted that [...]

Published
2013

33. Research from R.P. Collea and Colleagues Has Provided New Data on Breast Cancer

Subjects
Oncology, Experimental -- Reports, Women -- Health aspects, Breast cancer -- Research -- Care and treatment -- Reports, Cancer -- Research, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Breast Cancer are discussed in a new report. According to news reporting originating in Dallas, Texas, [...]

Published
2012

34. New Herceptin delivery method could vastly simplify breast cancer treatment

Subjects
Women -- Health aspects, Antineoplastic agents -- Analysis -- Methods -- Reports, Cancer -- Care and treatment, Breast cancer -- Drug therapy -- Analysis -- Methods -- Reports, Brand name products -- Analysis -- Methods -- Reports, Antimitotic agents -- Analysis -- Methods -- Reports, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

By a News Reporter-Staff News Editor at Women's Health Weekly -- A new method of delivering a commonly used breast cancer drug could result in considerably less time spent in [...]

Published
2012

35. Investigators from F. Hoffmann-La Roche Have Published New Data on Ovarian Cancer

Subjects
Hoffmann-La Roche Inc. -- Reports, Women -- Health aspects, Monoclonal antibodies -- Reports, Ovarian cancer -- Reports, Pharmaceutical industry -- Reports, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Ovarian Cancer are discussed in a new report. According to news originating from Nutley, New Jersey, [...]

Published
2012

36. Findings from University of Manitoba Provide New Insights into Carcinomas

Subjects
University of Manitoba -- Reports, Herceptin (Medication) -- Reports, Research, Reports, Universities and colleges -- Canada -- Manitoba -- Reports, Monoclonal antibodies -- Research -- Reports, Cancer -- Reports, Trastuzumab -- Research -- Reports
Abstract

Current study results from the report, 'Alterations in glycopeptides associated with herceptin treatment of human breast carcinoma mcf-7 and T-lymphoblastoid cells,' have been published. According to the authors of recent [...]

Published
2012

37. European Medicine Agency new product details:Herceptin

Subjects
Antineoplastic agents -- Reports, Business, international, Herceptin (Medication) -- Reports
Abstract

London: European Medicine Agency has issued the following new product details: This is a summary of the European public assessment report (EPAR) for Herceptin. It explains how the Committee for [...]

Published
2017

38. HER2-Positive Breast Cancer - Analysis by key industry drivers, restraints and challenges 2025

Subjects
Breast cancer -- Reports -- Forecasts and trends, Market trend/market analysis, Business, Business, international, Perjeta (Medication) -- Reports, Herceptin (Medication) -- Reports
Abstract

M2 PRESSWIRE-October 9, 2017-: HER2-Positive Breast Cancer - Analysis by key industry drivers, restraints and challenges 2025 (C)1994-2017 M2 COMMUNICATIONS RDATE:09102017 Pune, India -- WiseGuyReports announced addition of new report, [...]

Published
2017

39. MCOs Offering Both Medicare Advantage and Part D Plans are More Than Twice as Likely to Cover Avastin and Herceptin as a Drug Benefit on Their Medicare Advantage Plans

Subjects
Roche Holding AG -- Reports, Herceptin (Medication) -- Reports, Avastin (Medication) -- Reports, Care and treatment, Reports, Cancer treatment -- Reports, Health care costs -- Reports, Angiogenesis inhibitors -- Reports, Medicare -- Reports, Monoclonal antibodies -- Reports, Pharmaceutical industry -- Reports, Biological products -- Reports, Medical care, Cost of -- Reports, Cancer -- Care and treatment
Abstract

HealthLeaders-InterStudy and Fingertip Formulary find that surveyed pharmacy directors whose managed care organizations offer both a Medicare Advantage (MA) and a Part D plan were more than twice as likely [...]

Published
2010

40. New findings from K.P. Garnockjones and co-researchers in the area of breast cancer described

Subjects
Metastasis -- Care and treatment -- Reports, Cancer -- Care and treatment, Breast cancer -- Care and treatment -- Reports, Health, Women's issues/gender studies, Herceptin (Medication) -- Reports
Abstract

'Trastuzumab (Herceptin ®) is a humanized IgG(1) kappa monoclonal antibody, specifically targeted against the extracellular domain of the human epidermal growth factor receptor 2 (HER2), and is indicated for the [...]

Published
2010

41. Herceptin effective for gastric cancer, study finds

Subjects
Oncology, Experimental -- Drug therapy, Oncology, Experimental -- Reports, Stomach cancer -- Research, Stomach cancer -- Drug therapy, Stomach cancer -- Reports, Breast cancer -- Research, Breast cancer -- Drug therapy, Breast cancer -- Reports, Antimitotic agents -- Research, Antimitotic agents -- Reports, Antineoplastic agents -- Research, Antineoplastic agents -- Reports, Cancer -- Research, Cancer -- Drug therapy, Cancer -- Reports, Cancer -- Care and treatment, Business, Business, international, Health care industry, Herceptin (Medication) -- Reports
Published
2009

42. Findings from University Medical Center in the Area of Gastric Cancer Reported [Long-term trastuzumab (Herceptin [R]) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer]

Subjects
Herceptin (Medication) -- Reports, Care and treatment, Research, Reports, Stomach cancer -- Research -- Care and treatment -- Reports, Medical centers -- Reports, Cancer research -- Reports, Breast cancer -- Research -- Care and treatment -- Reports, Antineoplastic agents -- Research -- Reports
Abstract

2018 APR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology - Gastric Cancer have been published. According to news reporting [...]

Published
2018

43. Oncology Drug Report Featuring Herceptin & Trastuzumab: 2006-2015 Analysis & 2016-2021 Expectations - Research and Markets

Subjects
Stomach cancer -- Drug therapy -- Reports, Drug approval -- Reports, Biological products -- Reports, Trastuzumab -- Reports, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

DUBLIN -- Research and Markets has announced the addition of the 'Oncology Drug Report - Herceptin - Trastuzumab - 2006-2015 Analysis; 2016-2021 Expectations' report to their offering. Herceptin (trastuzumab): 2006-2015 [...]

Published
2016

44. Global Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight 2016: One of Roche's Three Her2+ Breast Cancer Drugs, Recorded a 15% Sales Increase in the US and a 10% Rise Overall - Research and Markets

Subjects
Breast cancer -- Reports, Trastuzumab -- Statistics -- Product development -- Reports, Business, News, opinion and commentary, Herceptin (Medication) -- Reports
Abstract

DUBLIN, October 21, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the http://www.researchandmarkets.com/research/lrq3xm/herceptin clinical trials to their offering. The Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight report gives [...]

Published
2016

45. Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight - Research and Markets

Subjects
Cancer treatment -- Reports, Medical research -- Reports, Trastuzumab -- Product development -- Reports, Business, Business, international, Herceptin (Medication) -- Reports
Abstract

DUBLIN -- Research and Markets has announced the addition of the 'Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight' clinical trials to their offering. The Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight report [...]

Published
2016

46. Breast cancer drug Herceptin increases heart damage risk, study says

Subjects
Cancer research -- Reports, Cardiac patients -- Drug therapy -- Reports, Breast cancer -- Risk factors -- Research -- Drug therapy -- Reports, Antineoplastic agents -- Research -- Reports, General interest, News, opinion and commentary, Herceptin (Medication) -- Reports
Abstract

Byline: STEPHEN FELLER TORONTO, April 20 (UPI) -- Although doctors already monitor older breast cancer patients for heart damage if their treatment includes the drug trastuzumab, researchers suggest all patients [...]

Published
2016

47. Event Brief of Q1 2012 PDL BioPharma Earnings Conference Call - Final

Subjects
JMP Securities L.L.C. -- Reports, Biological products industry -- Reports, Financial markets -- Reports, Investment banks -- Reports, Biotechnology industry -- Reports, Pharmaceutical industry -- Reports, Business, Herceptin (Medication) -- Reports, Avastin (Medication) -- Reports
Abstract

PARTICIPANTS . Jennifer Williams, Cook Williams Communications, IR . John McLaughlin, PDL BioPharma, Inc., President, CEO . Charles Duncan, JMP Securities, Analyst . Phil Nadeau, Cowen and Company, Analyst . [...]

Published
2012

48. PDL Biopharma Inc at Royal Bank Of Canada Global Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars -- Reports, Biological products industry -- Conferences, meetings and seminars -- Reports, Banks (Finance) -- Conferences, meetings and seminars -- Reports, Biological products -- Conferences, meetings and seminars -- Reports, Corporations -- Conferences, meetings and seminars -- Reports, Biotechnology industry -- Conferences, meetings and seminars -- Reports, Health care industry -- Conferences, meetings and seminars -- Reports, Pharmaceutical industry -- Conferences, meetings and seminars -- Reports, Health care industry, Business, Herceptin (Medication) -- Reports
Abstract

Presentation JASON KANTOR, ANALYST, RBC CAPITAL MARKETS: All right. Good afternoon. I'm Jason Kantor, one of the biotechnology analysts here at RBC. I want to welcome you to this afternoon's [...]

Published
2012

49. Full Year 2011 Chugai Pharmaceutical Co Ltd Earnings Presentation and Conference Call - Final

Subjects
Chugai Pharmaceutical Company Ltd. -- Reports -- Planning -- International economic relations, Roche Holding AG -- Reports -- Planning -- International economic relations, Sendai Earthquake and Tsunami, 2011 -- Reports -- Planning, Biological products industry -- International economic relations -- International trade -- Planning -- Reports, Corporations -- Reports, Stomach cancer -- Reports, Pharmaceutical industry -- International economic relations -- International trade -- Planning -- Reports, Company business planning, Business, Mircera (Medication) -- Reports, Herceptin (Medication) -- Reports, Tamiflu (Medication) -- Reports, Actemra (Medication) -- Reports, Avastin (Medication) -- Reports
Abstract

Presentation OSAMU NAGAYAMA, PRESIDENT AND CEO, CHUGAI PHARMACEUTICAL CO., LTD.: Good morning, everyone. Thank you very much indeed for gathering today despite this very cold weather. Three members from Chugai [...]

Published
2012

50. Q1 2012 ImmunoGen, Inc. Earnings Conference Call - Final

Subjects
Financial markets -- Reports, Company business planning, Business, Rituxan (Medication) -- Reports, Herceptin (Medication) -- Reports
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to the ImmunoGen first quarter fiscal year 2011 financial results conference call. (Operator instructions) Today's call is being recorded. At this time, for [...]

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results